News and Trends 30 Sep 2022
Treatment for hot flushes and night sweats accepted for regulatory review by EMA
A treatment for moderate to severe vasomotor symptoms (VMS) has been accepted by the European Medicines Agency (EMA) for regulatory review. Astellas Pharma Inc., submitted a marketing authorization application (MAA) for fezolinetant, an investigational oral, nonhormonal compound. VMS is characterized by hot flushes and/or night sweats which are common menopausal symptoms. Hot flushes The news […]